Bioregulators: what the word means.
"Bioregulator" is a name some sellers and researchers use for very short peptides, such as epitalon. It is a description, not a legal category: in its 2026 compounding reviews, the FDA assessed each peptide on its own.
- Evidence grade or review status for every compound
- Sources listed on every page
- US and sport status, dated
"Bioregulator" is a name some sellers and researchers use for very short peptides, such as epitalon. It is a description, not a legal category: in its 2026 compounding reviews, the FDA assessed each peptide on its own. Evidence attaches to each compound studied, never to a label, and epitalon is not an FDA-approved medicine.
Compounds studied in this area
Grades describe the published evidence, not a promise of any effect.
Is “bioregulator” a legal category?
What doesn’t the research on bioregulators show?
Saying what we don't know is part of the evidence.
Anything about bioregulators as a group: evidence attaches to each compound studied, never to a label.
Is epitalon an FDA-approved medicine? US and sport status
As of November 2026. See the full tracker and the changelog.
| Compound | FDA approval | 503A compounding (2026) | WADA (2026 List) |
|---|---|---|---|
| Epitalon | Not approved | FDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yet | Not named; S0 covers unapproved substances |
Worth knowing
Research use only
None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.
What research use only meansNo doses, ever
We publish no doses, protocols, or cycles for people, on any page.
Why we publish no dosesHow we grade evidence
Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.
Evidence gradesQuestions people ask
Is a bioregulator a kind of medicine?
Not as a group. The word is a description used by sellers and some researchers, and the FDA's 2026 compounding reviews assessed each peptide on its own. Check each compound's legal status in our tracker.
How should I read a claim about bioregulators?
Ask which compound, which study, in which model, and how many subjects. If a claim names only the label, it has no evidence behind it on our pages.
Sources
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149. PMID 19830585 (uses the term "peptide bioregulators"). pubmed.ncbi.nlm.nih.gov/19830585/
Start with the evidence
Every page sourced and dated, including what the research does not show.
Open the research library